JP2022017333A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022017333A5 JP2022017333A5 JP2021169396A JP2021169396A JP2022017333A5 JP 2022017333 A5 JP2022017333 A5 JP 2022017333A5 JP 2021169396 A JP2021169396 A JP 2021169396A JP 2021169396 A JP2021169396 A JP 2021169396A JP 2022017333 A5 JP2022017333 A5 JP 2022017333A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- human
- pharmaceutical composition
- population
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022176776A JP2023014100A (ja) | 2014-09-19 | 2022-11-02 | ＩＬ１３Ｒα２を標的とする共刺激性キメラ抗原受容体Ｔ細胞Ｌ１３Ｒα２を標的とする共刺激性キメラ抗原レセプターＴ細胞 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462053068P | 2014-09-19 | 2014-09-19 | |
| US62/053,068 | 2014-09-19 | ||
| JP2017515139A JP6657195B2 (ja) | 2014-09-19 | 2015-09-18 | Ｌ１３Ｒα２を標的とする共刺激性キメラ抗原レセプターＴ細胞 |
| JP2020017583A JP6986190B2 (ja) | 2014-09-19 | 2020-02-05 | ＩＬ１３Ｒα２を標的とする共刺激性キメラ抗原受容体Ｔ細胞Ｌ１３Ｒα２を標的とする共刺激性キメラ抗原レセプターＴ細胞 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020017583A Division JP6986190B2 (ja) | 2014-09-19 | 2020-02-05 | ＩＬ１３Ｒα２を標的とする共刺激性キメラ抗原受容体Ｔ細胞Ｌ１３Ｒα２を標的とする共刺激性キメラ抗原レセプターＴ細胞 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022176776A Division JP2023014100A (ja) | 2014-09-19 | 2022-11-02 | ＩＬ１３Ｒα２を標的とする共刺激性キメラ抗原受容体Ｔ細胞Ｌ１３Ｒα２を標的とする共刺激性キメラ抗原レセプターＴ細胞 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022017333A JP2022017333A (ja) | 2022-01-25 |
| JP2022017333A5 true JP2022017333A5 (enExample) | 2022-06-03 |
| JP7171871B2 JP7171871B2 (ja) | 2022-11-15 |
Family
ID=55533940
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017515139A Active JP6657195B2 (ja) | 2014-09-19 | 2015-09-18 | Ｌ１３Ｒα２を標的とする共刺激性キメラ抗原レセプターＴ細胞 |
| JP2017515138A Active JP6711819B2 (ja) | 2014-09-19 | 2015-09-21 | 養子ｔ細胞療法のためのセントラルメモリーｔ細胞 |
| JP2020017583A Active JP6986190B2 (ja) | 2014-09-19 | 2020-02-05 | ＩＬ１３Ｒα２を標的とする共刺激性キメラ抗原受容体Ｔ細胞Ｌ１３Ｒα２を標的とする共刺激性キメラ抗原レセプターＴ細胞 |
| JP2020093109A Active JP7216045B2 (ja) | 2014-09-19 | 2020-05-28 | 養子ｔ細胞療法のためのセントラルメモリーｔ細胞 |
| JP2021169396A Active JP7171871B2 (ja) | 2014-09-19 | 2021-10-15 | ＩＬ１３Ｒα２を標的とする共刺激性キメラ抗原受容体Ｔ細胞 |
| JP2022176776A Pending JP2023014100A (ja) | 2014-09-19 | 2022-11-02 | ＩＬ１３Ｒα２を標的とする共刺激性キメラ抗原受容体Ｔ細胞Ｌ１３Ｒα２を標的とする共刺激性キメラ抗原レセプターＴ細胞 |
| JP2023006410A Ceased JP2023052506A (ja) | 2014-09-19 | 2023-01-19 | 養子ｔ細胞療法のためのセントラルメモリーｔ細胞 |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017515139A Active JP6657195B2 (ja) | 2014-09-19 | 2015-09-18 | Ｌ１３Ｒα２を標的とする共刺激性キメラ抗原レセプターＴ細胞 |
| JP2017515138A Active JP6711819B2 (ja) | 2014-09-19 | 2015-09-21 | 養子ｔ細胞療法のためのセントラルメモリーｔ細胞 |
| JP2020017583A Active JP6986190B2 (ja) | 2014-09-19 | 2020-02-05 | ＩＬ１３Ｒα２を標的とする共刺激性キメラ抗原受容体Ｔ細胞Ｌ１３Ｒα２を標的とする共刺激性キメラ抗原レセプターＴ細胞 |
| JP2020093109A Active JP7216045B2 (ja) | 2014-09-19 | 2020-05-28 | 養子ｔ細胞療法のためのセントラルメモリーｔ細胞 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022176776A Pending JP2023014100A (ja) | 2014-09-19 | 2022-11-02 | ＩＬ１３Ｒα２を標的とする共刺激性キメラ抗原受容体Ｔ細胞Ｌ１３Ｒα２を標的とする共刺激性キメラ抗原レセプターＴ細胞 |
| JP2023006410A Ceased JP2023052506A (ja) | 2014-09-19 | 2023-01-19 | 養子ｔ細胞療法のためのセントラルメモリーｔ細胞 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US9914909B2 (enExample) |
| EP (4) | EP3587446A1 (enExample) |
| JP (7) | JP6657195B2 (enExample) |
| KR (3) | KR102683584B1 (enExample) |
| CN (4) | CN113789336B (enExample) |
| AU (4) | AU2015317351B2 (enExample) |
| BR (3) | BR112017005631A2 (enExample) |
| CA (2) | CA2961654A1 (enExample) |
| DK (1) | DK3200591T3 (enExample) |
| ES (2) | ES2738705T3 (enExample) |
| IL (6) | IL292650B2 (enExample) |
| MX (4) | MX387135B (enExample) |
| RU (2) | RU2749922C2 (enExample) |
| WO (2) | WO2016044811A1 (enExample) |
Families Citing this family (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104619334A (zh) | 2012-08-09 | 2015-05-13 | 利兰斯坦福初级大学董事会 | 超级因子和合成因子:具有新的和增强的信号传导活性的经改造细胞因子 |
| EP4282419A1 (en) | 2012-12-20 | 2023-11-29 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| US9657105B2 (en) | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| CA2925417C (en) | 2013-09-24 | 2023-10-24 | Fahar Merchant | Interleukin-4 receptor-binding fusion proteins and uses thereof |
| CN113307880B (zh) | 2014-01-13 | 2025-07-04 | 希望之城公司 | 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法 |
| BR112017005631A2 (pt) * | 2014-09-19 | 2018-06-26 | City Of Hope | células t com receptor de antígeno coestimulador quimérico direcionadas à il13ra2 |
| DK3298033T4 (da) | 2015-05-18 | 2023-10-02 | Tcr2 Therapeutics Inc | Sammensætninger og medicinske anvendelser til tcr-reprogrammering under anvendelse af fusionsproteiner |
| CN108348550A (zh) | 2015-07-21 | 2018-07-31 | 希望之城公司 | 用于表达嵌合抗原受体和其它受体的t细胞 |
| MX382532B (es) * | 2015-08-05 | 2025-03-13 | Cellabmed Inc | Receptor de antigeno quimerico y celulas t en las cuales se expresa el receptor de antigeno quimerico. |
| SG11201808411RA (en) | 2016-04-01 | 2018-10-30 | Kite Pharma Inc | Chimeric antigen and t cell receptors and methods of use |
| KR102397674B1 (ko) | 2016-04-01 | 2022-05-18 | 카이트 파마 인코포레이티드 | Bcma 결합 분자 및 그의 사용 방법 |
| WO2017173410A1 (en) * | 2016-04-01 | 2017-10-05 | Amgen Inc. | Chimeric receptors to flt3 and methods of use thereof |
| UA128781C2 (uk) | 2016-04-01 | 2024-10-23 | Кайт Фарма, Інк. | Т-клітина, спосіб її отримання та застосування |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| WO2017192536A1 (en) | 2016-05-02 | 2017-11-09 | University Of Kansas | Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy |
| CN109641012A (zh) * | 2016-06-07 | 2019-04-16 | 马克思-德布鲁克-分子医学中心亥姆霍兹联合会 | 与bcma结合的嵌合抗原受体和car-t细胞 |
| WO2017214333A1 (en) * | 2016-06-08 | 2017-12-14 | Intrexon Corporation | Cd33 specific chimeric antigen receptors |
| JP7109789B2 (ja) | 2016-08-02 | 2022-08-01 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法 |
| NZ751571A (en) * | 2016-09-16 | 2025-10-31 | Baylor College Medicine | Platform for activation and expansion of virus-specific t-cells |
| BR112019007100A2 (pt) | 2016-10-07 | 2019-06-25 | Tcr2 Therapeutics Inc | composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão |
| JP7291396B2 (ja) | 2016-11-22 | 2023-06-15 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法 |
| US20200095547A1 (en) | 2016-12-02 | 2020-03-26 | Darya ALIZADEH | Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors |
| WO2018106972A1 (en) * | 2016-12-07 | 2018-06-14 | La Jolla Institute For Allergy And Immunology | Compositions for cancer treatment and methods and uses for cancer treatment and prognosis |
| WO2018132427A1 (en) | 2017-01-10 | 2018-07-19 | The General Hospital Corporation | Targeted t cells with cytotoxicity toward immunosuppressive cells |
| CN110612119B (zh) | 2017-02-07 | 2024-10-29 | 西雅图儿童医院（Dba西雅图儿童研究所） | 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂 |
| CN108395481B (zh) * | 2017-02-08 | 2021-02-05 | 西比曼生物科技（香港）有限公司 | 一种靶向cd20的car的构建及其工程化t细胞的活性鉴定 |
| US12083148B2 (en) * | 2017-02-22 | 2024-09-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | IL13Ra2-binding chimeric antigen receptors |
| WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
| BR112019019941B1 (pt) * | 2017-03-27 | 2023-12-05 | Noile-Immune Biotech, Inc | Polinucleotídeo compreendendo uma sequência de base que codifica o receptor de antígeno quimérico, vetor e método |
| JP7505885B2 (ja) | 2017-04-14 | 2024-06-25 | ザ ジェネラル ホスピタル コーポレイション | 腫瘍微小環境を標的にするキメラ抗原受容体ｔ細胞 |
| CA3060443A1 (en) | 2017-04-19 | 2018-10-25 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
| CN107267555B (zh) * | 2017-05-27 | 2020-03-20 | 上海优卡迪生物医药科技有限公司 | 一种基于octs技术的恶性胶质瘤car-t治疗载体及其构建方法和应用 |
| WO2019033030A1 (en) * | 2017-08-11 | 2019-02-14 | City Of Hope | ONCOLYTIC VIRUS EXPRESSING A CAR-T CELL TARGET AND USES THEREOF |
| AU2018347796B2 (en) | 2017-10-10 | 2025-07-24 | Medicenna Therapeutics, Inc. | IL-4-fusion formulations for treatment of central nervous system (CNS) tumors |
| CN111542545A (zh) * | 2017-11-03 | 2020-08-14 | 索伦托治疗有限公司 | Cd38定向嵌合抗原受体构建体 |
| US20200345823A1 (en) * | 2017-11-07 | 2020-11-05 | Xiuli Wang | Treatment of cns lymphoma and systemic lymphoma with intracerebroventricularly administered cd19 car |
| CN109971721B (zh) * | 2017-12-28 | 2023-10-31 | 上海细胞治疗研究院 | 自表达cd47抗体的间皮素特异性car-t细胞及其用途 |
| CN109971712B (zh) * | 2017-12-28 | 2023-06-20 | 上海细胞治疗研究院 | 特异性靶向cd19抗原且高水平稳定表达pd-1抗体的car-t细胞及用途 |
| CN120154716A (zh) | 2018-01-22 | 2025-06-17 | 恩多塞特公司 | Car t细胞的使用方法 |
| WO2019148006A1 (en) * | 2018-01-26 | 2019-08-01 | City Of Hope | Chimeric antigen receptors and methods for reducing off target toxicity |
| CN111936518A (zh) * | 2018-02-06 | 2020-11-13 | 西雅图儿童医院（Dba西雅图儿童研究所） | 对fl-ple标记的肿瘤表现出最佳的t细胞功能的荧光素特异性car |
| EP3752170A4 (en) * | 2018-02-12 | 2022-03-30 | The General Hospital Corporation | CHEMERA ANTIGEN RECEPTORS TARGETING THE MICROENVIRONMENT |
| JP7273421B2 (ja) | 2018-02-21 | 2023-05-15 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用 |
| TW202000229A (zh) | 2018-02-23 | 2020-01-01 | 美商安德賽特公司 | Car t細胞療法之順序方法 |
| EP3765487A4 (en) * | 2018-03-14 | 2022-01-05 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | ZETAKINE-DIRECTED T-LYMPHOCYTE IMMUNOTHERAPY, TARGETING THE IL-13 ALPHA 2 RECEPTOR |
| JP7438123B2 (ja) * | 2018-03-14 | 2024-02-26 | シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） | 腫瘍特異的Ｔ細胞免疫療法用のＩＬ－１３受容体α２（ＩＬ１３Ｒα２）標的キメラ抗原受容体 |
| EP3773632A4 (en) | 2018-04-06 | 2022-05-18 | The Regents of The University of California | Methods of treating egfrviii expressing glioblastomas |
| EP3773633A4 (en) | 2018-04-06 | 2022-01-26 | The Regents of The University of California | METHODS OF TREATMENT OF GLIOBLASTOMA |
| CA3099712A1 (en) * | 2018-05-21 | 2019-11-28 | Biosceptre (Uk) Limited | Chimeric antigen receptors with modified linker domains and uses thereof |
| CA3102097A1 (en) * | 2018-06-01 | 2019-12-05 | The Board Of Trustees Of The Leland Stanford Junior Unversity | Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof |
| WO2019239213A2 (en) | 2018-06-01 | 2019-12-19 | Medicenna Therapeutics Inc. | Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof |
| US12281151B2 (en) | 2018-06-29 | 2025-04-22 | City Of Hope | CD6 targeted chimeric antigen receptors for treatment of certain autoimmune disorders |
| WO2020032780A1 (ko) * | 2018-08-10 | 2020-02-13 | 주식회사 유틸렉스 | 암항원 특이적 세포독성 t세포 |
| JP2022512922A (ja) * | 2018-11-06 | 2022-02-07 | ワシントン・ユニバーシティ | キメラ抗原受容体記憶様（ｃａｒｍｌ）ｎｋ細胞ならびにその産生および使用方法 |
| US20230065784A1 (en) | 2019-03-21 | 2023-03-02 | City Of Hope | Composition and method for reducing expression of checkpoint inhibitors in t cells expressing a car or ctl |
| US20220145252A1 (en) | 2019-03-29 | 2022-05-12 | City Of Hope | Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors |
| US20220249560A1 (en) * | 2019-05-24 | 2022-08-11 | City Of Hope | Ccr4 targeted chimeric antigen receptor modified t cells for treatment of ccr4 positive malignancies |
| WO2021004400A1 (zh) * | 2019-07-06 | 2021-01-14 | 苏州克睿基因生物科技有限公司 | 一种表达cd3抗体受体复合物的免疫细胞及其用途 |
| CN112204135A (zh) * | 2019-07-06 | 2021-01-08 | 苏州克睿基因生物科技有限公司 | 一种表达cd3抗体受体复合物的免疫细胞及其用途 |
| PH12022550102A1 (en) * | 2019-07-24 | 2022-11-21 | Regeneron Pharma | Chimeric antigen receptors with mage-a4 specificity and uses thereof |
| EP3769816A1 (en) * | 2019-07-25 | 2021-01-27 | Ospedale Pediatrico Bambino Gesù | Car-cd123 vector and uses thereof |
| EP4084808A1 (en) | 2019-12-30 | 2022-11-09 | City of Hope | Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers |
| CN115551882A (zh) * | 2020-01-31 | 2022-12-30 | 希望之城公司 | 用于治疗IL13Rα2阳性恶性病的靶向性嵌合抗原受体修饰的T细胞 |
| US20230374085A1 (en) * | 2020-03-11 | 2023-11-23 | City Of Hope | Dual-targeting chimeric antigen receptor modified t cells comprising il-13 and chlorotoxin for cancer treatment |
| WO2021183960A1 (en) * | 2020-03-12 | 2021-09-16 | City Of Hope | TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF IL13RαA2 POSITIVE MALIGNANCIES |
| BR112022021551A2 (pt) | 2020-04-28 | 2023-01-03 | Lyell Immunopharma Inc | Métodos para cultivar células |
| US20230220419A1 (en) * | 2020-05-27 | 2023-07-13 | The Medical College Of Wisconsin, Inc. | Improved Lentiviral Vector Transfer Plasmid and Methods of Use |
| GB202011993D0 (en) | 2020-07-31 | 2020-09-16 | Adc Therapeutics Sa | ANTI-IL 13Ra2 antibodies |
| JP2023537133A (ja) * | 2020-08-11 | 2023-08-30 | イェダ リサーチ アンド デベロップメント カンパニー リミテッド | ベトｃａｒ－ｔ細胞 |
| WO2022056085A2 (en) * | 2020-09-10 | 2022-03-17 | Mustang Bio, Inc. | Combination therapy comprising cancer-targeted car-t cells and a method of using same for a treatment for cancer |
| US20240009239A1 (en) * | 2020-11-04 | 2024-01-11 | Fred Hutchinson Cancer Center | Therapeutic targeting of mesothelin in acute myeloid leukemia with chimeric antigen receptor t cell therapy |
| US20230364138A1 (en) | 2020-11-23 | 2023-11-16 | City Of Hope | Engineered t cells for expression of chimeric anitgen receptors |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| MX2023006395A (es) | 2020-12-03 | 2023-06-15 | Century Therapeutics Inc | Celulas dise?adas geneticamente y usos de estas. |
| AU2021401052A1 (en) | 2020-12-18 | 2023-06-22 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| CN118146395A (zh) * | 2021-02-08 | 2024-06-07 | 浙江大学 | 一种以内源性蛋白质分子替代单结构域抗体的嵌合抗原受体 |
| KR20230148837A (ko) | 2021-02-25 | 2023-10-25 | 라이엘 이뮤노파마, 인크. | Ror1 표적화 키메라 항원 수용체 |
| KR20230175198A (ko) * | 2021-03-18 | 2023-12-29 | 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 | IL13Rα2를 표적으로 하는 DNA 암호화 이중특이적 항체 및 이를 암 치료에 사용하는 방법 |
| CN117242090A (zh) | 2021-03-30 | 2023-12-15 | 希望之城公司 | CAR T细胞疗法和IFNγ |
| US20230190799A1 (en) * | 2021-07-21 | 2023-06-22 | City Of Hope | Chimeric antigen receptor t cells targeting cea and anti-cea-il2 immunocytokines for cancer therapy |
| CN113621077B (zh) * | 2021-09-02 | 2023-01-31 | 山东大学 | 一种tim-3/cd28融合蛋白及所述融合蛋白修饰的car-t细胞 |
| EP4176895A1 (en) * | 2021-11-08 | 2023-05-10 | AvenCell Europe GmbH | Targeting modules against il13ra2 or her2 for use in combination with a chimeric antigen receptor |
| WO2023130462A1 (zh) * | 2022-01-10 | 2023-07-13 | 卡瑞济(北京)生命科技有限公司 | 靶向IL13Rα2的嵌合抗原受体及其用途 |
| CN115960257B (zh) * | 2022-09-29 | 2023-10-27 | 卡瑞济(北京)生命科技有限公司 | 靶向IL13Rα2的经优化的嵌合抗原受体及其用途 |
| EP4588939A1 (en) | 2024-01-16 | 2025-07-23 | Universitat de Barcelona | Interleukin-13 receptor subunit alpha-2 (il13ralpha2) targeting moieties for the treatment and prevention of il13ralpha2-positive cancer |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE145428T1 (de) | 1990-12-14 | 1996-12-15 | Cell Genesys Inc | Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen |
| US5712149A (en) | 1995-02-03 | 1998-01-27 | Cell Genesys, Inc. | Chimeric receptor molecules for delivery of co-stimulatory signals |
| CA2209300C (en) * | 1995-02-24 | 2011-06-28 | The General Hospital Corporation | Redirection of cellular immunity by receptor chimeras |
| GB9526131D0 (en) | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Recombinant chimeric receptors |
| US6576232B1 (en) | 1998-04-03 | 2003-06-10 | The Penn State Research Foundation | IL13 mutants |
| DK1100529T4 (da) | 1998-07-30 | 2010-12-20 | Us Gov Health & Human Serv | Thymosin beta 4 fremmer sårheling |
| US6410319B1 (en) | 1998-10-20 | 2002-06-25 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| AU1599301A (en) * | 1999-11-11 | 2001-06-06 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Modulating IL-13 activity using mutated IL-13 molecules that are antagonists or agonists of IL-13 |
| US7560280B2 (en) | 2000-11-03 | 2009-07-14 | Kourion Therapeutics Gmbh | Human cord blood derived unrestricted somatic stem cells (USSC) |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| US7514537B2 (en) | 2001-04-30 | 2009-04-07 | City Of Hope | Chimeric immunoreceptor useful in treating human gliomas |
| US11278594B2 (en) * | 2001-04-30 | 2022-03-22 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| AU2002256390B2 (en) | 2001-04-30 | 2007-08-30 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| DE60316428T2 (de) | 2003-07-24 | 2008-01-10 | Matsushita Electric Industrial Co., Ltd., Kadoma | Verfahren, Kodierer und Kommunikationsvorrichtung zur Kodierung von parallel verketteten Daten |
| US20050113564A1 (en) | 2003-11-05 | 2005-05-26 | St. Jude Children's Research Hospital | Chimeric receptors with 4-1BB stimulatory signaling domain |
| US7754441B2 (en) * | 2003-11-17 | 2010-07-13 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
| DE102004043271A1 (de) * | 2004-09-07 | 2006-03-09 | Linde Ag | Verfahren zur Synthese von Zirkoniumcarboxylaten |
| DK1814580T3 (en) * | 2004-11-24 | 2016-12-12 | Hutchinson Fred Cancer Res | Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens |
| BRPI0620187A2 (pt) * | 2005-12-21 | 2011-11-01 | Sentoclone Ab | método para a expansão de linfócitos t auxiliares cd4+ e/ou linfócitos t cd8+ reativos a tumor, linfócito-t reativo a tumor, composição farmacêutica, métodos para tratar um indivìduo sofrendo de uma doença de origem neoplástica e para realizar a regressão de tumor em um indivìduo, uso de linfócitos-t reativos a tumor, e, kit |
| EP1963551A4 (en) * | 2005-12-21 | 2009-07-29 | Univ Montreal | MARKINGS FOR MEMORY T CELLS AND USES THEREOF |
| LT2126054T (lt) | 2007-01-31 | 2016-10-10 | Yeda Research And Development Company Limited | Peradresuotos, genetiškai modifikuotos t reguliavimo ląstelės ir jų naudojimas autoimuninės ir uždegiminės ligos slopinimui |
| ES2667729T3 (es) * | 2007-09-26 | 2018-05-14 | Ucb Biopharma Sprl | Fusiones de anticuerpos con doble especificidad |
| EP4032552B1 (en) * | 2008-08-26 | 2023-10-04 | City of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| EP2516458A1 (en) * | 2009-12-22 | 2012-10-31 | Novartis AG | Tetravalent cd47-antibody constant region fusion protein for use in therapy |
| GB2481983A (en) * | 2010-07-12 | 2012-01-18 | Hart Fenton & Co Ltd | A ship including a gas tank room |
| WO2012024203A1 (en) * | 2010-08-18 | 2012-02-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of identifying central memory t cells and obtaining antigen-specific t cell populations |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| JP6203705B2 (ja) * | 2011-03-23 | 2017-09-27 | フレッド ハッチンソン キャンサー リサーチ センター | 細胞免疫療法のための方法および組成物 |
| HRP20181690T4 (hr) * | 2011-03-29 | 2025-01-03 | Roche Glycart Ag | Varijante protutijela fc |
| EP2532740A1 (en) * | 2011-06-11 | 2012-12-12 | Michael Schmück | Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy |
| EP2814846B1 (en) * | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| PH12019550223A1 (en) * | 2012-08-20 | 2024-02-19 | Fred Hutchinson Cancer Center | Method and compositions for cellular immunotherapy |
| US9657105B2 (en) * | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| CN113307880B (zh) * | 2014-01-13 | 2025-07-04 | 希望之城公司 | 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法 |
| BR112017005631A2 (pt) * | 2014-09-19 | 2018-06-26 | City Of Hope | células t com receptor de antígeno coestimulador quimérico direcionadas à il13ra2 |
-
2015
- 2015-09-18 BR BR112017005631-3A patent/BR112017005631A2/pt not_active IP Right Cessation
- 2015-09-18 KR KR1020177010183A patent/KR102683584B1/ko active Active
- 2015-09-18 BR BR122024000360-0A patent/BR122024000360A2/pt not_active Application Discontinuation
- 2015-09-18 MX MX2017003596A patent/MX387135B/es unknown
- 2015-09-18 WO PCT/US2015/051089 patent/WO2016044811A1/en not_active Ceased
- 2015-09-18 EP EP19175730.1A patent/EP3587446A1/en not_active Withdrawn
- 2015-09-18 CN CN202110969587.7A patent/CN113789336B/zh active Active
- 2015-09-18 JP JP2017515139A patent/JP6657195B2/ja active Active
- 2015-09-18 RU RU2017111298A patent/RU2749922C2/ru active
- 2015-09-18 CN CN201580061133.2A patent/CN107002084B/zh active Active
- 2015-09-18 IL IL292650A patent/IL292650B2/en unknown
- 2015-09-18 EP EP15775539.8A patent/EP3194433B1/en active Active
- 2015-09-18 IL IL308324A patent/IL308324A/en unknown
- 2015-09-18 AU AU2015317351A patent/AU2015317351B2/en active Active
- 2015-09-18 ES ES15775539T patent/ES2738705T3/es active Active
- 2015-09-18 CA CA2961654A patent/CA2961654A1/en active Pending
- 2015-09-21 MX MX2017003557A patent/MX383042B/es unknown
- 2015-09-21 RU RU2017111300A patent/RU2763523C2/ru active
- 2015-09-21 EP EP15842405.1A patent/EP3200591B2/en active Active
- 2015-09-21 ES ES15842405T patent/ES2876235T5/es active Active
- 2015-09-21 IL IL251188A patent/IL251188B/en unknown
- 2015-09-21 WO PCT/US2015/051280 patent/WO2016044853A1/en not_active Ceased
- 2015-09-21 EP EP21166086.5A patent/EP3916084A1/en active Pending
- 2015-09-21 KR KR1020177010184A patent/KR102610715B1/ko active Active
- 2015-09-21 CN CN202110690954.XA patent/CN113637640A/zh active Pending
- 2015-09-21 KR KR1020237041649A patent/KR20230169455A/ko not_active Ceased
- 2015-09-21 JP JP2017515138A patent/JP6711819B2/ja active Active
- 2015-09-21 BR BR112017005630-5A patent/BR112017005630B1/pt not_active IP Right Cessation
- 2015-09-21 CN CN201580062281.6A patent/CN107404881B/zh active Active
- 2015-09-21 CA CA2961676A patent/CA2961676A1/en active Pending
- 2015-09-21 DK DK15842405.1T patent/DK3200591T3/da active
-
2016
- 2016-05-27 US US15/167,869 patent/US9914909B2/en active Active
-
2017
- 2017-03-15 IL IL251196A patent/IL251196B/en active IP Right Grant
- 2017-03-16 MX MX2021006400A patent/MX2021006400A/es unknown
- 2017-03-17 MX MX2021012720A patent/MX2021012720A/es unknown
-
2018
- 2018-03-12 US US15/918,901 patent/US10676717B2/en active Active
-
2020
- 2020-02-05 JP JP2020017583A patent/JP6986190B2/ja active Active
- 2020-05-06 US US16/867,803 patent/US20200318069A1/en active Pending
- 2020-05-28 JP JP2020093109A patent/JP7216045B2/ja active Active
- 2020-06-03 AU AU2020203651A patent/AU2020203651A1/en not_active Abandoned
-
2021
- 2021-02-02 IL IL280576A patent/IL280576B/en unknown
- 2021-10-15 JP JP2021169396A patent/JP7171871B2/ja active Active
- 2021-11-30 AU AU2021277651A patent/AU2021277651A1/en not_active Abandoned
-
2022
- 2022-05-08 IL IL292828A patent/IL292828A/en unknown
- 2022-11-02 JP JP2022176776A patent/JP2023014100A/ja active Pending
-
2023
- 2023-01-19 JP JP2023006410A patent/JP2023052506A/ja not_active Ceased
-
2024
- 2024-02-28 AU AU2024201326A patent/AU2024201326A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022017333A5 (enExample) | ||
| JP2022051744A5 (enExample) | ||
| US20240148821A1 (en) | Pharmaceutical use of cyclic peptide compound | |
| ES2661500T3 (es) | Variantes de HMGB1 y sus usos | |
| AU2008296733B2 (en) | VEGFR-1/NRP-1 targeting peptides | |
| AU2012257774C1 (en) | High-affinity, dimeric inhibitors of PSD-95 as efficient neuroprotectants against ischemic brain damage and for treatment of pain | |
| ES2926511T3 (es) | Anticuerpos anti-CLEVER-1 humanizados y utilización de los mismos | |
| CN102307896A (zh) | 基于ⅲ型纤连蛋白结构域的支架组合物、方法及用途 | |
| US11993645B2 (en) | Compositions comprising R-Spondin (RSPO) surrogate molecules | |
| JP2006513724A5 (enExample) | ||
| JP2011504458A5 (enExample) | ||
| AR066794A1 (es) | Proteina de union que comprende un dominio de union a antigeno que se une al globulomero beta amiloide (20-42), anticuerpos, molecula de acido nucleico que la codifica vector, celula huesped, metodo para su produccion, usos, composicion farmaceutia y metodo de diagnostico | |
| JP2014519852A5 (enExample) | ||
| US11041157B2 (en) | Slit2D2-HSA fusion protein and use thereof against tumours | |
| CN107973838A (zh) | 一种促进皮肤损伤修复的小分子多肽及其应用 | |
| JP2015533372A5 (enExample) | ||
| RU2017104284A (ru) | Выделенные полипептиды cd44 и их применение | |
| ES2987275T3 (es) | Péptido antagonista de la actividad de la interleucina-15 | |
| CN107805282A (zh) | 一种靶向疗法和免疫疗法联合的多肽 | |
| CN107446024B (zh) | 一种可拮抗ddx3蛋白rna结合活性的多肽dip-13及其应用 | |
| KR20180086277A (ko) | 폴리펩티드 화합물, 그리고 이의 제조 방법 및 적용 | |
| JP2005512509A5 (enExample) | ||
| CN108084247B (zh) | 一种合成多肽及其合成方法和应用 | |
| CN108676071B (zh) | 一种抗Aβ蛋白聚集的七肽及其应用与编码该合成多肽的基因 | |
| JP2018510213A5 (enExample) |